BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35781448)

  • 1. [Role of NO-cGMP-PKG axis in pulmonary arterial hypertension].
    Watanabe H
    Nihon Yakurigaku Zasshi; 2022; 157(4):221-225. PubMed ID: 35781448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
    Triposkiadis F; Xanthopoulos A; Skoularigis J; Starling RC
    Heart Fail Rev; 2022 Nov; 27(6):1991-2003. PubMed ID: 35437713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to the nitric oxide/cyclic guanosine 5'-monophosphate/protein kinase G pathway in vascular smooth muscle cells from the obese Zucker rat, a classical animal model of insulin resistance: role of oxidative stress.
    Russo I; Del Mese P; Doronzo G; Mattiello L; Viretto M; Bosia A; Anfossi G; Trovati M
    Endocrinology; 2008 Apr; 149(4):1480-9. PubMed ID: 18079207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The vasodilatory effect of sulfur dioxide via SGC/cGMP/PKG pathway in association with sulfhydryl-dependent dimerization.
    Yao Q; Huang Y; Liu AD; Zhu M; Liu J; Yan H; Zhang Q; Geng B; Gao Y; Du S; Huang P; Tang C; Du J; Jin H
    Am J Physiol Regul Integr Comp Physiol; 2016 Jun; 310(11):R1073-80. PubMed ID: 27009048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sildenafil inhibits hypoxia-induced transient receptor potential canonical protein expression in pulmonary arterial smooth muscle via cGMP-PKG-PPARγ axis.
    Wang J; Yang K; Xu L; Zhang Y; Lai N; Jiang H; Zhang Y; Zhong N; Ran P; Lu W
    Am J Respir Cell Mol Biol; 2013 Aug; 49(2):231-40. PubMed ID: 23526219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes.
    Goulopoulou S; Hannan JL; Matsumoto T; Ogbi S; Ergul A; Webb RC
    Am J Physiol Heart Circ Physiol; 2015 Jul; 309(2):H297-304. PubMed ID: 25957216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease.
    Zuccarello E; Acquarone E; Calcagno E; Argyrousi EK; Deng SX; Landry DW; Arancio O; Fiorito J
    Biochem Pharmacol; 2020 Jun; 176():113818. PubMed ID: 31978378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preservation of nitric oxide-induced relaxation of porcine coronary artery: roles of the dimers of soluble guanylyl cyclase, phosphodiesterase type 5, and cGMP-dependent protein kinase.
    Liu J; Chen Z; Ye L; Liu H; Dou D; Liu L; Yu X; Gao Y
    Pflugers Arch; 2014 Oct; 466(10):1999-2008. PubMed ID: 24413911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
    Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT
    Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The NO/cGMP/PKG pathway in platelets: The therapeutic potential of PDE5 inhibitors in platelet disorders.
    Degjoni A; Campolo F; Stefanini L; Venneri MA
    J Thromb Haemost; 2022 Nov; 20(11):2465-2474. PubMed ID: 35950928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclic guanosine monophosphate modulates accumulation of phosphodiesterase 5 inhibitors in human platelets.
    Bajraktari G; Burhenne J; Bugert P; Haefeli WE; Weiss J
    Biochem Pharmacol; 2017 Dec; 145():54-63. PubMed ID: 28964803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuated vasodilatation in lambs with endogenous and exogenous activation of cGMP signaling: role of protein kinase G nitration.
    Aggarwal S; Gross CM; Kumar S; Datar S; Oishi P; Kalkan G; Schreiber C; Fratz S; Fineman JR; Black SM
    J Cell Physiol; 2011 Dec; 226(12):3104-13. PubMed ID: 21351102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell carcinoma.
    Tuttle TR; Mierzwa ML; Wells SI; Fox SR; Ben-Jonathan N
    Cancer Lett; 2016 Jan; 370(2):279-85. PubMed ID: 26551887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling.
    Li N; Xi Y; Tinsley HN; Gurpinar E; Gary BD; Zhu B; Li Y; Chen X; Keeton AB; Abadi AH; Moyer MP; Grizzle WE; Chang WC; Clapper ML; Piazza GA
    Mol Cancer Ther; 2013 Sep; 12(9):1848-59. PubMed ID: 23804703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble guanylate cyclase stimulators in pulmonary hypertension.
    Stasch JP; Evgenov OV
    Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway.
    Martínez-Salamanca JI; La Fuente JM; Cardoso J; Fernández A; Cuevas P; Wright HM; Angulo J
    J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble Guanylate Cyclase Stimulators and Activators: Where are We and Where to Go?
    Xiao S; Li Q; Hu L; Yu Z; Yang J; Chang Q; Chen Z; Hu G
    Mini Rev Med Chem; 2019; 19(18):1544-1557. PubMed ID: 31362687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Dasgupta A; Bowman L; D'Arsigny CL; Archer SL
    Clin Pharmacol Ther; 2015 Jan; 97(1):88-102. PubMed ID: 25670386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The bradykinin-cGMP-PKG pathway augments insulin sensitivity via upregulation of MAPK phosphatase-5 and inhibition of JNK.
    Frigolet ME; Thomas G; Beard K; Lu H; Liu L; Fantus IG
    Am J Physiol Endocrinol Metab; 2017 Sep; 313(3):E321-E334. PubMed ID: 28679626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3,7-Bis(2-hydroxyethyl)icaritin, a potent inhibitor of phosphodiesterase-5, prevents monocrotaline-induced pulmonary arterial hypertension via NO/cGMP activation in rats.
    Lan TH; Chen XL; Wu YS; Qiu HL; Li JZ; Ruan XM; Xu DP; Lin DQ
    Eur J Pharmacol; 2018 Jun; 829():102-111. PubMed ID: 29665366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.